Purpose: To isolate cancer testis antigens that are expressed in pancreatic cancers and may be useful in clinical applications.
Experimental Design: To efficiently isolate cancer testis antigens, a testis cDNA library was immunoscreened (SEREX) with serum from a patient with pancreatic ductal adenocarcinoma. The expression of isolated antigens in various cancer cell lines and tissues was evaluated by reverse transcription-PCR and Northern blot analyses. The immunogenicity of the antigen in cancer patients was evaluated by detection of the IgG antibody in sera from patients with various cancers.
Results: Of the three clones isolated through screening of a total of 2 x 10(6) cDNA library clones, one clone (KU-CT-1) was found to be expressed in various cancers but only in testis among normal tissues, indicating that it was a novel cancer testis antigen. The KU-CT-1 gene is located on chromosome 10p12 and produces two splice variants, which encode proteins of 397 and 872 amino acids, respectively. KU-CT-1 was expressed in pancreatic cancer tissues (3 of 9, 33%), lung cancer tissues (9 of 24, 38%), and endometrial cancer tissues (7 of 11, 64%). Specific serum IgG antibodies were detected in 3 of 20 pancreatic cancer patients, 2 of 12 endometrial cancer patients, 1 of 18 colon cancer patients, and 1 of 10 prostate cancer patients but not detected in 30 healthy individuals.
Conclusions: KU-CT-1 is a new cancer testis antigen that is expressed in pancreatic, lung, and endometrial cancers and may be useful for diagnosis and immunotherapy for patients with various cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-05-1206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What is ethically required to adapt to intellectual disability in cancer care? A case study of testicular cancer management.
J Intellect Dev Disabil
December 2023
Peter MacCallum Cancer Centre, Melbourne, Australia.
Background: People with intellectual disability who require cancer services face several barriers and inequities, including delayed or unrecognised cancer diagnosis and inadequate attention paid to their specific concerns, needs and preferences about care.
Methods: In this case report, we present a case report of a 33-year-old male with severe intellectual disability requiring treatment for metastatic testicular cancer. The patient's intellectual disability required major adjustments to the delivery of chemotherapy.
Testicular cryopreservation: From technical aspects to practical applications.
Histol Histopathol
January 2025
Laboratory of Animal Germplasm Conservation, Federal Rural University of the Semiarid Region - UFERSA, Mossoró, RN, Brazil.
Testicular cryopreservation has been highlighted as a promising alternative for preserving male fertility and can be applied to restore spermatogenesis in prepubertal individuals or cancer patients, preserve biologically valuable genotypes, and in studies on reproductive physiology or toxicity of various substances. This review presents an analysis of the technical aspects and applications of testicular cryopreservation, examining the contributions of important studies in this area and discussing the different factors that can impact the efficiency of the technique. Testicular fragments can be obtained from living or dead individuals, at any age and reproductive stage, through orchiectomy or biopsy.
View Article and Find Full Text PDFNetworks of pre-diagnostic circulating RNA in testicular germ cell tumour.
Sci Rep
January 2025
Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Testicular germ cell tumour (TGCT) is a malignancy with known inherited risk factors, affecting young men. We have previously identified several hundred differentially abundant circulating RNAs in pre-diagnostic serum from TGCT cases compared to healthy controls. In this study, we performed Weighted Gene Co-expression Network Analysis (WGCNA) on mRNA and miRNA data from these samples.
View Article and Find Full Text PDFATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201.
EBioMedicine
January 2025
State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, 100021, China. Electronic address:
Background: Small cell lung cancer (SCLC) represents a highly aggressive neuroendocrine tumour with a dismal prognosis. Currently, the identification of a specific tumour antigen that can facilitate immune-based therapies for SCLC remains elusive.
Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyse cancer/testis antigens (CTAs) in SCLC cell lines and human tumour specimens.
Melanoma antigen gene-A2 (MAGE-A2) is one of the most cancer-testis antigens overexpressed in a variety of malignancies. However, the expression of MAGE-A2 for clinical values in the pathophysiology of renal cell carcinoma (RCC) is unknown. For the first time, the present study was conducted to examine the expression and prognostic significance of MAGE-A2 expression in clear cell RCC (ccRCC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!